World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 17 October 2012
Main ID:  NCT00522184
Date of registration: 27/08/2007
Primary sponsor: Centre Hospitalier Universitaire de Nice
Public title: Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study
Scientific title: Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study for Evaluation of Efficacy and Safety of Etanercept Versus Intra-Articular Steroid Injection in Acute Synovitis
Date of first enrolment: February 2005
Target sample size: 34
Recruitment status: Completed
URL:  http://clinicaltrials.gov/show/NCT00522184
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment  
Countries of recruitment
France
Contacts
Name:   Christian H ROUX
Address: 
Telephone:
Email:
Affiliation:  Rheumatology department, Nice
Key inclusion & exclusion criteria

Inclusion Criteria:

- must be able to understand the information about the study

- diagnosis of rheumatoid arthritis for 6 month at least

- suffering for 2 weeks at least

- with evaluation of pain over 4/10

- with stable DMARDs treatment for three month at least

Exclusion Criteria:

- infection or surgery on the target joint

- treated with infliximab,adalimumab or anakinra



Age minimum: 18 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Rheumatoid Arthritis
Intervention(s)
Procedure: intra-articular injection of etanercept
Procedure: intra-articular injection of steroid
Primary Outcome(s)
Pain [Time Frame: every month during six month]
Secondary Outcome(s)
Secondary ID(s)
02-PP-04
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Wyeth is now a wholly owned subsidiary of Pfizer
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history